GSK to SCOTUS: Don't take up 'skinny' generic drug label case
GSK made clear to the US Supreme Court on Friday that it should not revive its case against Teva Pharmaceuticals regarding so-called “skinny” generic drug labels, where certain indications are carved out so generics can come to market more quickly.
In opposition to Teva’s petition last month, calling on SCOTUS to protect the longstanding precedent of skinny generic labels, GSK now claims that this case does not present threats to “generic companies who operate properly under the law of induced infringement as applied to generic drug labels—’skinny’ or not. And, it concerns circumstances highly unlikely to be repeated, as well as regulations and policies FDA has changed multiple times.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.